Trademark: 87891754
Word
LLDX
Status
Dead
Status Code
606
Status Date
Monday, January 10, 2022
Serial Number
87891754
Mark Type
4000
Filing Date
Tuesday, April 24, 2018
Published for Opposition
Tuesday, April 9, 2019
Abandoned Date
Monday, January 10, 2022

Trademark Owner History
LeukoLifeDx, Inc. - Owner At Publication

Classifications
1 Assays and reagents for research purposes; diagnostic preparations for scientific use; diagnostic reagents for scientific research relating to molecular identification and digital quantification; diagnostic test kits for scientific use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation therefor; diagnostic test kits comprising reagents for scientific research relating to molecular identification and digital quantification; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for clinicalor medical laboratory use, namely, reagents for proteomics, RNA transcription and microRNA expression profiling, small-molecule analysis, single nucleotide polymorphisms analysis, DNA sequencing, detection of polymorphisms in human fluids,detection of copy number variations, and clinical, oncology, and hematology diagnostics; reagents for scientific or medical research use, diagnostic preparations and reagents for scientific or research uses, namely, RNA transcription profiling, proteomics, clinical diagnostics of samples containing microorganisms or human fluids, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing; test kits, consisting of chemical preparations for scientific purposes, in particular for the detection, diagnosis, progress monitoring and progress prediction of diseases, including inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers; assays, reagents, enzymes, polymerases, buffers and nucleotides, and kits comprised thereof, all for scientific or research use; diagnostic reagents for scientific in vitro use in biochemistry, clinical chemistry and microbiology, RNA and microRNA expression transcription profiling, proteomics, clinical diagnostics, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing
5 Gene therapy products, namely, living and genetically engineered tissues for use in predictive and diagnostic medical purposes; medical diagnostic reagents; medical diagnostic reagents and assays fortesting and predicting patient recovery; medical diagnostic reagents and assaysfor testing of bodily fluids for use indisease detection; diagnostic test kitsfor medical use comprising reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical diagnostic test kits for detecting pathogens, comprising reagents for medical use; medical diagnostic reagents for RNA transcription and microRNA expression profiling, proteomics, small molecule analysis, single nucleotide polymorphisms analysis, DNA sequencing, detection of polymorphismsin human fluids, detection of copy number variations, and clinical, oncology, and hematology diagnostics; medical diagnostic reagents and diagnostic reagents for clinical or medical laboratory use, diagnostic reagents for medical in vitro use in biochemistry, clinical chemistry and microbiology, RNA and microRNA expression transcription profiling, proteomics, clinical diagnostics, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing; tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use; medical diagnostic reagents and assays for testing ofbody fluids; kits consisting primarily of medical diagnostic reagents and assays for testing of body fluids; reagents in the form of cell markers and molecule markers for medical purposes
42 Custom design and development of chemical reagents and biochemical assays; research and product development services for others in the field of biotechnology; providing laboratory research services in the field of gene expression; genetic data mining; providing molecule identification methods for acquiring, analyzing and managing biological and genetic information, in the fields of genetics and environment; research and development services for others in the field of diagnostic compounds for use in medicine, measuring apparatus for use in product research and development, separation and purification processes, environmental and testing processes, and industrial quality control processes; developing systems foracquiring, analyzing, and managing biological and genetic information in the fields of diagnostic reagents, forensics, medicine, genetics, and environment; research, design, and development services for others in the fields of diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, separation and purification processes, environmental and testing processes and industrial quality control processes; chemical screening analysis for others
44 Medical diagnostic testing, monitoring and reporting services; genetic medical testing service; providing medical information to patients and medical professionals in the form of reports in a wide variety of medical fields; medical services; providing information relating to diagnostic, prophylactic and therapeutic properties of assays and reagents; providing medical record analysis services designed to provide patients and medical professionals with custom tailored information about the range of possible diagnoses and therapies
LEUKO LIFE DX

Trademark Events
Jan 10, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Jan 10, 2022
Abandonment - No Use Statement Filed
Jun 4, 2021
Notice Of Approval Of Extension Request E-Mailed
Jun 2, 2021
Extension 4 Granted
Jun 2, 2021
Extension 4 Filed
Jun 2, 2021
Teas Extension Received
Nov 26, 2020
Notice Of Approval Of Extension Request E-Mailed
Nov 24, 2020
Extension 3 Granted
Nov 24, 2020
Extension 3 Filed
Nov 24, 2020
Teas Extension Received
Jun 5, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 3, 2020
Extension 2 Granted
Jun 3, 2020
Extension 2 Filed
Jun 3, 2020
Teas Extension Received
Nov 19, 2019
Notice Of Approval Of Extension Request E-Mailed
Nov 15, 2019
Extension 1 Granted
Nov 15, 2019
Extension 1 Filed
Nov 15, 2019
Teas Extension Received
Jun 4, 2019
Noa E-Mailed - Sou Required From Applicant
Apr 9, 2019
Official Gazette Publication Confirmation E-Mailed
Apr 9, 2019
Published For Opposition
Mar 20, 2019
Notification Of Notice Of Publication E-Mailed
Mar 1, 2019
Teas/Email Correspondence Entered
Mar 1, 2019
Correspondence Received In Law Office
Mar 1, 2019
Assigned To Lie
Feb 26, 2019
Teas Response To Office Action Received
Feb 27, 2019
Approved For Pub - Principal Register
Feb 27, 2019
Examiner's Amendment Entered
Feb 27, 2019
Notification Of Examiners Amendment E-Mailed
Feb 27, 2019
Examiners Amendment E-Mailed
Feb 27, 2019
Examiners Amendment -Written
Aug 27, 2018
Notification Of Non-Final Action E-Mailed
Aug 27, 2018
Non-Final Action E-Mailed
Aug 27, 2018
Non-Final Action Written
Aug 14, 2018
Assigned To Examiner
May 3, 2018
New Application Office Supplied Data Entered In Tram
Apr 27, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24